The clinical practice of new cancer drugs is an important milestone in the development of new drugs. The development of new cancer drugs has been relatively long, so many cancer patients cannot wait for the successful development of new cancer drugs. The new cancer drug 3D185 is currently entering the clinical stage and is expected to solve the problem of cancer patients having no medicine to take at this stage!
3D185 is a small molecule inhibitor of fibroblast growth factor receptor 1, 2, 3 (FGFR 1, 2, 3). 3D185 has the advantages of strong anti-tumor activity, excellent PD-PK characteristics, low toxicity and high bioavailability. It also has CSF1-R targeting effect. It is suitable for tumor treatment and combined treatment with PD-1/PD-L1.

new cancer drugs are jointly carried out by many tertiary hospitals . Shanghai Oriental Hospital Professor Li Jin served as the main researcher of the project. New cancer drugs are not only clinically carried out in China, but also recognized by the medical community in the United States!

There are 33 new cancer drugs that have been admitted to the treatment quota. Cancer clinical practice is usually approved by the ethics committee. There are many benefits in the treatment. It is expected that patients will be treated with cancer before they can be put into clinical treatment. If patients want to join, they can ask me!
Enrollment conditions
- Age ≥ 18 years old;
- There is an evaluable cancer in
- Expected survival ≥ 12 weeks;
- family members agree to clinical treatment!